These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 37527886)

  • 1. Protocol of Tecopox study: a multicentre, open-label, double-arm trial to evaluate the efficacy and safety of oral tecovirimat therapy for patients with smallpox or monkeypox.
    Suzuki T; Saito S; Tsuzuki S; Ashida S; Takakusaki M; Yoshikawa T; Shimojima M; Ebihara H; Ohmagari N; Morioka S
    BMJ Open; 2023 Aug; 13(8):e069550. PubMed ID: 37527886
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
    Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J
    Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Glance at the Development and Patent Literature of Tecovirimat: The First-in-Class Therapy for Emerging Monkeypox Outbreak.
    Almehmadi M; Allahyani M; Alsaiari AA; Alshammari MK; Alharbi AS; Hussain KH; Alsubaihi LI; Kamal M; Alotaibi SS; Alotaibi AN; Aldhafeeri AA; Imran M
    Viruses; 2022 Aug; 14(9):. PubMed ID: 36146675
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oral Tecovirimat for the Treatment of Smallpox.
    Grosenbach DW; Honeychurch K; Rose EA; Chinsangaram J; Frimm A; Maiti B; Lovejoy C; Meara I; Long P; Hruby DE
    N Engl J Med; 2018 Jul; 379(1):44-53. PubMed ID: 29972742
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New Perspectives on Antimicrobial Agents: Tecovirimat for Treatment of Human Monkeypox Virus.
    DeLaurentis CE; Kiser J; Zucker J
    Antimicrob Agents Chemother; 2022 Dec; 66(12):e0122622. PubMed ID: 36374026
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment with the smallpox antiviral tecovirimat (ST-246) alone or in combination with ACAM2000 vaccination is effective as a postsymptomatic therapy for monkeypox virus infection.
    Berhanu A; Prigge JT; Silvera PM; Honeychurch KM; Hruby DE; Grosenbach DW
    Antimicrob Agents Chemother; 2015 Jul; 59(7):4296-300. PubMed ID: 25896687
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and viral dynamics of tecovirimat in patients with MPOX: A multicenter open-label, double-arm trial in Japan.
    Akiyama Y; Morioka S; Tsuzuki S; Yoshikawa T; Yamato M; Nakamura H; Shimojima M; Takakusaki M; Saito S; Takahashi K; Sanada M; Komatsubara M; Takebuchi K; Yamaguchi E; Suzuki T; Shimokawa K; Kurosu T; Kawahara M; Oishi K; Ebihara H; Ohmagari N
    J Infect Chemother; 2024 Jun; 30(6):488-493. PubMed ID: 38042298
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Co-administration of tecovirimat and ACAM2000™ in non-human primates: Effect of tecovirimat treatment on ACAM2000 immunogenicity and efficacy versus lethal monkeypox virus challenge.
    Russo AT; Berhanu A; Bigger CB; Prigge J; Silvera PM; Grosenbach DW; Hruby D
    Vaccine; 2020 Jan; 38(3):644-654. PubMed ID: 31677948
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Monkeypox treatment: Current evidence and future perspectives.
    Khani E; Afsharirad B; Entezari-Maleki T
    J Med Virol; 2023 Jan; 95(1):e28229. PubMed ID: 36253931
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Phase I/II Clinical Trial to evaluate the efficacy of baricitinib to prevent respiratory insufficiency progression in onco-hematological patients affected with COVID19: A structured summary of a study protocol for a randomised controlled trial.
    Moreno-González G; Mussetti A; Albasanz-Puig A; Salvador I; Sureda A; Gudiol C; Salazar R; Marin M; Garcia M; Navarro V; de la Haba Vaca I; Coma E; Sanz-Linares G; Dura X; Fontanals S; Serrano G; Cruz C; Mañez R
    Trials; 2021 Feb; 22(1):116. PubMed ID: 33546739
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of nelfinavir in asymptomatic and mild COVID-19 patients: a structured summary of a study protocol for a multicenter, randomized controlled trial.
    Hosogaya N; Miyazaki T; Fukushige Y; Takemori S; Morimoto S; Yamamoto H; Hori M; Kurokawa T; Kawasaki Y; Hanawa M; Fujii Y; Hanaoka H; Iwami S; Watashi K; Yamagoe S; Miyazaki Y; Wakita T; Izumikawa K; Yanagihara K; Mukae H; Kohno S;
    Trials; 2021 Apr; 22(1):309. PubMed ID: 33910617
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Double-blind, randomized, controlled, trial to assess the efficacy of allogenic mesenchymal stromal cells in patients with acute respiratory distress syndrome due to COVID-19 (COVID-AT): A structured summary of a study protocol for a randomised controlled trial.
    Payares-Herrera C; Martínez-Muñoz ME; Vallhonrat IL; de Molina RM; Torres MP; Trisan A; de Diego IS; Alonso R; Zafra R; Donaire T; Sánchez R; Rubio JJ; Duarte Palomino RF; Solá CA
    Trials; 2021 Jan; 22(1):9. PubMed ID: 33407777
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Overview of the regulatory approval of tecovirimat intravenous formulation for treatment of smallpox: potential impact on smallpox outbreak response capabilities, and future tecovirimat development potential.
    Russo AT; Grosenbach DW; Honeychurch KM; Long PG; Hruby DE
    Expert Rev Anti Infect Ther; 2023 Mar; 21(3):235-242. PubMed ID: 36728515
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Testing the efficacy and safety of BIO101, for the prevention of respiratory deterioration, in patients with COVID-19 pneumonia (COVA study): a structured summary of a study protocol for a randomised controlled trial.
    Dioh W; Chabane M; Tourette C; Azbekyan A; Morelot-Panzini C; Hajjar LA; Lins M; Nair GB; Whitehouse T; Mariani J; Latil M; Camelo S; Lafont R; Dilda PJ; Veillet S; Agus S
    Trials; 2021 Jan; 22(1):42. PubMed ID: 33430924
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and efficacy of antiviral combination therapy in symptomatic patients of Covid-19 infection - a randomised controlled trial (SEV-COVID Trial): A structured summary of a study protocol for a randomized controlled trial.
    Panda PK; Bandyopadhyay A; Singh BC; Moirangthem B; Chikara G; Saha S; Bahurupi YA
    Trials; 2020 Oct; 21(1):866. PubMed ID: 33081849
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of nitazoxanide plus atazanavir/ritonavir for the treatment of moderate to severe COVID-19 (NACOVID): A structured summary of a study protocol for a randomised controlled trial.
    Olagunju A; Fowotade A; Olagunoye A; Ojo TO; Adefuye BO; Fagbamigbe AF; Adebiyi AO; Olagunju OI; Ladipo OT; Akinloye A; Adeagbo BA; Onayade A; Bolaji OO; Happi C; Rannard S; Owen A
    Trials; 2021 Jan; 22(1):3. PubMed ID: 33397457
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An overview of tecovirimat for smallpox treatment and expanded anti-orthopoxvirus applications.
    Russo AT; Grosenbach DW; Chinsangaram J; Honeychurch KM; Long PG; Lovejoy C; Maiti B; Meara I; Hruby DE
    Expert Rev Anti Infect Ther; 2021 Mar; 19(3):331-344. PubMed ID: 32882158
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hydroxychloroquine efficacy and safety in preventing SARS-CoV-2 infection and COVID-19 disease severity during pregnancy (COVID-Preg): a structured summary of a study protocol for a randomised placebo controlled trial.
    González R; García-Otero L; Pons-Duran C; Marbán-Castro E; Goncé A; Llurba E; Gil MDM; Rodríguez-Zambrano MÁ; Chen H; Ramírez M; Bardají A; Menendez C
    Trials; 2020 Jul; 21(1):607. PubMed ID: 32616063
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical Use of Tecovirimat (Tpoxx) for Treatment of Monkeypox Under an Investigational New Drug Protocol - United States, May-August 2022.
    O'Laughlin K; Tobolowsky FA; Elmor R; Overton R; O'Connor SM; Damon IK; Petersen BW; Rao AK; Chatham-Stephens K; Yu P; Yu Y;
    MMWR Morb Mortal Wkly Rep; 2022 Sep; 71(37):1190-1195. PubMed ID: 36107794
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.